Related Experiment Video
Updated: Dec 7, 2025

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
Published on: October 20, 2020
How can oral paediatric formulations be improved? A challenge for the XXI century
Miguel Moreira1, Mafalda Sarraguça1
1LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Insights
Improving pediatric oral formulations is crucial due to safety risks from off-label use. Innovative strategies like crystal engineering and 3D printing are needed to enhance drug palatability and compliance in children.
Area of Science:
- Pharmaceutical Sciences
- Pediatric Medicine
- Drug Delivery Systems
Background:
- Paediatric oral formulations require significant improvement to ensure patient safety and efficacy.
- Lack of approved paediatric medicines leads to off-label prescribing, increasing adverse drug reaction risks.
- Product acceptability, influenced by user and product characteristics, is vital for paediatric medication formulation.
Purpose of the Study:
- To provide an overview of paediatric oral formulations, focusing on palatability challenges.
- To discuss innovative approaches for improving the palatability of paediatric medicines.
- To highlight advancements in developing specialized paediatric drug delivery systems.
Main Methods:
- Review of current literature on paediatric oral formulation development.
- Analysis of regulatory guidelines for paediatric medicine specialization.
- Exploration of innovative palatability enhancement techniques.
Main Results:
- Oral solid dosage forms are preferred over liquids for improved stability and shelf-life.
- Palatability and size remain significant challenges for paediatric solid dosage forms.
- Innovative methods like crystal engineering, candy-like forms, and 3D printing show promise.
Conclusions:
- Enhancing palatability is essential for improving medication compliance in children.
- Novel approaches are necessary to overcome existing palatability issues in paediatric formulations.
- Crystal engineering, novel pharmaceutical forms, and 3D printing offer promising avenues for paediatric drug development.
Abstract:
Paediatric oral formulations need to be improved. This is an indisputable fact that has gain attention from the regulators, the medical staff, and researchers. The lack of adequate medicines developed for children, resulted in several off-label and unlicensed prescriptions, increasing the risks of adverse drug reactions. When formulating a paediatric medicine, it is necessary to consider the product acceptability determined by the characteristics of both product and user (Gerrard et al., 2019). In the last decades, the regulators have issued guidelines to facilitate the development of medicines specialized for children. The use of oral solid dosage forms instead of liquid dosage forms has been preferred due to advantages, e.g., increase stability and shelf-life. However, palatability and size are common difficulties in solid forms. Many aspects need to be considered when developing a new oral paediatric formulation, although, palatability is recognized as a common reason for non-compliance among children. There are many methods that can be used to improve palatability; however, innovative approaches are still needed. In this review, an overview on oral paediatric formulations with emphasis on their palatability is given. Some of the most innovative approaches are discussed, for example, the use of crystal engineering to improve drug palatability, the development of candy-like pharmaceutical forms, and the use of 3D printing to develop personalized medicines for children.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Bioavailability Enhancement: Drug Permeability Enhancement
Pharmacokinetics in Pediatric Patients: Drug Excretion
Bioavailability Enhancement: Drug Solubility Enhancement
Drug Dosing: Infants and Children
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

